Akston Bioscience: “Akston Biosciences Announces Commercial Supply Agreement of Seppic’s Adjuvant to Formulate Akston Shelf-stable COVID-19 Vaccine at Global Scale;New data shows protein-based AKS-452 vaccine is shelf-stable for six months at 25° C (77° F)”

Share

Related Posts